Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 /
The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily l...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
1989.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Prologue
- Chemical Structure
- Pharmacological Profile of SandostatinR
- Carcinoid Tumours and the Carcinoid Syndrome
- Tumors of the Gastroenteropancreatic Axis
- The Use of SandostatinR in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis
- SandostatinR: Assay and Efficacy in VIPoma and Insulinoma
- SandostatinR in Digestive Endocrine Tumors
- VIPoma, Gastrinoma and Glucagonoma
- Rebound Effect and Escape of Diarrhea Inhibition Using SandostatinR in VIPoma Patients
- Long-Term Treatment of VIPoma and Glucagonoma with SandostatinR
- Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma
- SandostatinR in the Treatment of Advanced Malignancies
- Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with SandostatinR
- SandostatinR and Gastroenteropancreatic Endocrine Tumors
- Therapeutic Characteristics
- Consensus
- Future Directions
- Bibliography.